Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study

Immune checkpoint inhibitors (ICIs) elicit antitumour effects by activating the host immunity and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI-ILD) is a fatal irAE that is difficult to treat; moreover, its incidence is relatively higher in patients with lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Naoto, Matsuoka, Rie, Sakurada, Takumi, Goda, Mitsuhiro, Chuma, Masayuki, Yagi, Kenta, Zamami, Yoshito, Nishioka, Yasuhiko, Ishizawa, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426925/
https://www.ncbi.nlm.nih.gov/pubmed/32792640
http://dx.doi.org/10.1038/s41598-020-70743-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426925/
https://www.ncbi.nlm.nih.gov/pubmed/32792640
http://dx.doi.org/10.1038/s41598-020-70743-2

Ejemplares similares